Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490678 | 0.82 | HPGD (0.52) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL16132794 | 0.80 | HSD17B10 (0.50) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL24599711 | 0.80 | HSD17B10 (0.50) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL776675 | 0.80 | MAPT (0.50) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL9957227 | 0.78 | MAPT (0.48) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL22310446 | 0.77 | MAPT (0.46) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL10722629 | 0.75 | HPGD (0.44) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL16724698 | 0.75 | ALDH1A1 (0.39) | HPGDMAPTSMN1; SMN2HSD17B10SLC6A4 | |
| SCHEMBL775811 | 0.74 | MAPT (0.55) | HPGDMAPTSMN1; SMN2MGLLHSD17B10 | |
| SCHEMBL21183168 | 0.73 | HDAC4 (0.40) | HPGDMAPTSMN1; SMN2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-11820864-B2 | Aqueous polyglycidol synthesis with ultra-low branching | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11795225-B2 | Therapeutic binding molecules | MEDIMMUNE LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795225-B2 | Therapeutic binding molecules | MEDIMMUNE LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20230310636-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230295293-A1 | BINDING MOLECULES AGAINST FRa | ASTRAZENECA AB (SE) | 2023-09-21 | — | — | US | disclosed |
| US-20230183358-A1 | ANTIBODY MOLECULES AND CONJUGATES | MEDIMMUNE LLC | 2023-06-15 | — | — | US | disclosed |
| US-20130011728-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-01-10 | — | — | US | disclosed |
| US-20120177988-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2450997-A1 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | Mitsubishi Chemical Corporation (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120070731-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2418723-A1 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | Mitsubishi Chemical Corporation (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-2378602-A2 | Nonaqueous electrolyte for recherable battery, and recharchable battery with nonaqueous electrolyte | Mitsubishi Chemical Corporation (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20100119956-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2144321-A1 | NONAQUEOUS ELECTROLYTE FOR RECHARGEABLE BATTERY, AND RECHARGEABLE BATTERY WITH NONAQUEOUS ELECTROLYTE | Mitsubishi Chemical Corporation (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-20090325065-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2012386-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183358-A1 | ANTIBODY MOLECULES AND CONJUGATES | MET, EGFR, ERBB2 | HPGD 4709/4885MAPT 2300/4885SMN1; SMN2 4618/4885 |
| US-20230310636-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | PARP1, PARP11, PARP12 | HPGD 3517/4885MAPT 3117/4885SMN1; SMN2 2446/4885 |
| US-11795225-B2 | Therapeutic binding molecules | EPCAM, IGSF11, FCGR3B | HPGD 4034/4885MAPT 1237/4885SMN1; SMN2 4645/4885 |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | EPCAM, IGSF11, FCGR3B | HPGD 4034/4885MAPT 1237/4885SMN1; SMN2 4645/4885 |
| US-20230295293-A1 | BINDING MOLECULES AGAINST FRa | FRG1, FRS2, TFRC | HPGD 4501/4885MAPT 3147/4885SMN1; SMN2 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.